ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:BPAX
- CUSIP: N/A
- Web: www.anipharmaceuticals.com
- Trailing P/E Ratio:
- Foreward P/E Ratio: -1.28
- P/E Growth:
- Net Margins: 5.99%
- Return on Equity: 6.12%
- Return on Assets: 3.00%
Frequently Asked Questions for ANI Pharmaceuticals (NASDAQ:BPAX)
What is ANI Pharmaceuticals' stock symbol?
ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "BPAX."
Who are some of ANI Pharmaceuticals' key competitors?
Some companies that are related to ANI Pharmaceuticals include Incyte Corporation (INCY), Quintiles Transitional Holdings (Q), Alkermes PLC (ALKS), Alnylam Pharmaceuticals (ALNY), Qiagen N.V. (QGEN), Seattle Genetics (SGEN), Ionis Pharmaceuticals (IONS), United Therapeutics Corporation (UTHR), Icon Plc (ICLR), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), Exact Sciences Corporation (EXAS), PAREXEL International Corporation (PRXL), Bio-Techne Corp (TECH), ACADIA Pharmaceuticals (ACAD), WuXi PharmaTech (Cayman) (WX), Sage Therapeutics (SAGE) and Portola Pharmaceuticals (PTLA).
Who are ANI Pharmaceuticals' key executives?
ANI Pharmaceuticals' management team includes the folowing people:
- Robert E. Brown Jr., Independent Chairman of the Board
- Arthur S. Przybyl, President, Chief Executive Officer, Director
- Stephen P. Carey, Chief Financial Officer, Vice President
- James G. Marken, Vice President - Operations
- Mark J. Ginski Ph.D., Vice President of Corticotropin Product Development
- Karen Quinn Ph.D., Vice President - Corticotropin Regulatory Affairs
- Robert W. Schrepfer, Vice President - New Business Development and Contract Manufacturing
- Fred E. Holubow, Independent Director
- Tracy L. Marshbanks Ph.D., Independent Director
- Thomas A. Penn, Independent Director
How do I buy ANI Pharmaceuticals stock?
Shares of ANI Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ANI Pharmaceuticals' stock price today?
MarketBeat Community Rating for ANI Pharmaceuticals (NASDAQ BPAX)MarketBeat's community ratings are surveys of what our community members think about ANI Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of ANI Pharmaceuticals stock can currently be purchased for approximately $1.09.
Consensus Ratings for ANI Pharmaceuticals (NASDAQ:BPAX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for ANI Pharmaceuticals (NASDAQ:BPAX)
(Data available from 8/17/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/26/2015||Roth Capital||Boost Price Target||$1.00 -> $3.00||N/A|
Earnings History for ANI Pharmaceuticals (NASDAQ:BPAX)Earnings History by Quarter for ANI Pharmaceuticals (NASDAQ BPAX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for ANI Pharmaceuticals (NASDAQ:BPAX)
Current Year EPS Consensus Estimate: $-1.50 EPS
Next Year EPS Consensus Estimate: $-0.85 EPS
Dividend History for ANI Pharmaceuticals (NASDAQ:BPAX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for ANI Pharmaceuticals (NASDAQ:BPAX)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for ANI Pharmaceuticals (NASDAQ:BPAX)
Latest Headlines for ANI Pharmaceuticals (NASDAQ:BPAX)
ANI Pharmaceuticals (BPAX) Chart for Thursday, August, 17, 2017